Gene patents, patenting life and the impact of court rulings on US stem cell patents and research

• ​저자명

Kirstin RW Matthews, Maude L Cuchiara

• 학술지명

Regenerative Medicine

• 권호사항

Vol. 9, Nol 2

• 발행처

Regenerative Medicine

• 자료유형

국외학술지

• 수록면

191-200

• 언어

English

• 발행년도

2014. 03

• Abstract

In June 2013, the US Supreme Court ruled that naturally occurring genes were unpatentable in the case Association for Molecular Pathology v. Myriad Genetics . Up until this decision, Myriad Genetics was the only company in the USA that could legally conduct diagnostic testing for BRCA1 and 2 , genes that are linked to familial breast and ovarian cancer. The court case and rulings garnered discussion in public about patenting biological materials. This paper will describe the progression of the Myriad Genetics case, similar US rulings and biological intellectual property policies. In addition, it will discuss the impact of the case on biological patents - specifically those for human embryonic stem cells.